Schrodinger SDGR Drug discovery — Total revenues

Other product segments

Similar metrics at other companies

RCUSLicense and development services — Total revenues

$12M-40.0%

NBIXReportable Segment — Total revenues

$814.5M+42.2%

TARSLicense fees and collaboration revenue — Total revenues

$16.67M—

KNSAPharmaceutical — Revenue

$214.27M+55.5%

BIIBTotal Revenue

$2.48B+1.9%

ABCLResearch fees — Total Revenue

$8.12M+99.7%

Questions, answered.

What is Schrodinger's drug discovery — total revenues?

Schrodinger (SDGR) reported drug discovery — total revenues of $22.88M in Q1 2026.

How has Schrodinger's drug discovery — total revenues changed year-over-year?

Schrodinger's drug discovery — total revenues increased by 123.5% year-over-year, from $10.24M to $22.88M.

What is the long-term trend for Schrodinger's drug discovery — total revenues?

Over 4 years (2021 to 2025), Schrodinger's drug discovery — total revenues has grown at a 22.6% compound annual growth rate (CAGR), from $24.7M to $55.87M.

What does drug discovery — total revenues mean?

This is the aggregate revenue recognized by the drug discovery segment from all sources, including service fees and milestone payments. It serves as the primary indicator of the segment's overall market demand and commercial success.